• Stock declines to ₹175.44, down 7.20% in the session
  • Fall follows Q4 results showing weak profitability
  • Price reaction reflects cautious sentiment despite stable revenue

Overview

Nath Bio-Genes Ltd (NSE: NATHBIOGEN) is trading near ₹175.44, down 7.20% in the latest session. The decline comes immediately after the company reported its Q4 results, triggering a negative market reaction. The stock had seen a recent recovery phase, but the latest earnings outcome appears to have interrupted that momentum.

Fundamental View

For the quarter ended March 2026, the company reported total income of ₹5,396.78 lakh. Profit before tax stood at ₹249.04 lakh, while net profit came in at -₹0.92 lakh, with earnings per share at -₹0.79.
While revenue remained stable, the shift to a marginal net loss seems to have impacted sentiment. The divergence between operating performance and bottom-line outcome suggests pressure on margins or costs, which may be a concern for investors in the near term.

Technical View

Technically, NATHBIOGEN is trading above its 50-day SMA near ₹152.74, indicating that the broader trend still holds. However, the recent session shows a sharp rejection from higher levels near ₹180.00, reflecting supply at elevated prices.
The 14-day RSI near 57.30 has cooled from higher levels, indicating easing momentum and a shift toward a more neutral setup after the recent decline.

Key Technical Levels

Support is placed at ₹163.00–₹150.00, which may act as a near-term cushion. On the upside, resistance is seen at ₹188.00–₹200.00, where the stock may face pressure if it attempts to recover.

Risks

• Marginal net loss despite positive revenue
  • Pressure on profitability and margins
  • Possible continuation of near-term correction
  • Volatility following earnings reaction

Summary

Nath Bio-Genes Ltd (NSE: NATHBIOGEN) has declined following its Q4 results, with the marginal loss at the net level weighing on sentiment. While the broader structure remains relatively stable, the recent reaction indicates caution among market participants.
The near-term direction will depend on whether the stock stabilizes around support levels or continues to adjust following the earnings outcome.

FAQs

Why did NATHBIOGEN stock fall today?
The stock declined after Q4 results showed a marginal net loss, impacting sentiment.

Is the trend still positive?
The stock remains above its 50-day average, but momentum has eased.

What levels should investors track?
Support near ₹163.00–₹150.00 and resistance around ₹188.00–₹200.00.